JP2018522039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522039A5 JP2018522039A5 JP2018505460A JP2018505460A JP2018522039A5 JP 2018522039 A5 JP2018522039 A5 JP 2018522039A5 JP 2018505460 A JP2018505460 A JP 2018505460A JP 2018505460 A JP2018505460 A JP 2018505460A JP 2018522039 A5 JP2018522039 A5 JP 2018522039A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- patient
- tβrii
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028537 myelofibrosis Diseases 0.000 claims description 74
- 239000005557 antagonist Substances 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 108010024121 Janus Kinases Proteins 0.000 claims description 34
- 102000015617 Janus Kinases Human genes 0.000 claims description 34
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 32
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 32
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 12
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 10
- 229960000215 ruxolitinib Drugs 0.000 claims description 10
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims description 9
- 108091000080 Phosphotransferase Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 102000020233 phosphotransferase Human genes 0.000 claims description 8
- 208000008601 Polycythemia Diseases 0.000 claims description 5
- 208000005485 Thrombocytosis Diseases 0.000 claims description 5
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 5
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 claims description 4
- 229950003487 fedratinib Drugs 0.000 claims description 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 253
- 208000035475 disorder Diseases 0.000 description 34
- 206010016654 Fibrosis Diseases 0.000 description 31
- 230000004761 fibrosis Effects 0.000 description 31
- 230000011132 hemopoiesis Effects 0.000 description 29
- 208000007536 Thrombosis Diseases 0.000 description 26
- 210000000056 organ Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 24
- 208000014767 Myeloproliferative disease Diseases 0.000 description 23
- 230000002757 inflammatory effect Effects 0.000 description 22
- 206010061218 Inflammation Diseases 0.000 description 20
- 230000004054 inflammatory process Effects 0.000 description 20
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 16
- 206010041660 Splenomegaly Diseases 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 12
- 206010043554 thrombocytopenia Diseases 0.000 description 12
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 11
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 11
- 208000017733 acquired polycythemia vera Diseases 0.000 description 11
- 208000037244 polycythemia vera Diseases 0.000 description 11
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 10
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229960001330 hydroxycarbamide Drugs 0.000 description 10
- 102100029968 Calreticulin Human genes 0.000 description 9
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 8
- 108010079292 betaglycan Proteins 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 206010029410 night sweats Diseases 0.000 description 8
- 230000036565 night sweats Effects 0.000 description 8
- 208000016261 weight loss Diseases 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 238000009120 supportive therapy Methods 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 6
- 206010006002 Bone pain Diseases 0.000 description 6
- 206010059186 Early satiety Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 206010040021 Sensory abnormalities Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010065973 Iron Overload Diseases 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 201000000023 Osteosclerosis Diseases 0.000 description 4
- 206010041648 Splenic infarction Diseases 0.000 description 4
- 206010047571 Visual impairment Diseases 0.000 description 4
- 206010000059 abdominal discomfort Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 208000015294 blood coagulation disease Diseases 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 206010019847 hepatosplenomegaly Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 208000013465 muscle pain Diseases 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 208000004235 neutropenia Diseases 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 208000029257 vision disease Diseases 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 description 3
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 3
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 3
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 3
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 3
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 3
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 3
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 3
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 3
- 101000721176 Homo sapiens Protein DBF4 homolog B Proteins 0.000 description 3
- 101000616523 Homo sapiens SH2B adapter protein 3 Proteins 0.000 description 3
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 description 3
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 3
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 3
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 3
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 3
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 3
- 102100025199 Protein DBF4 homolog B Human genes 0.000 description 3
- 102100021778 SH2B adapter protein 3 Human genes 0.000 description 3
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 3
- 102100034195 Thrombopoietin Human genes 0.000 description 3
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- -1 PK1-587 Chemical compound 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 description 1
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 206010072206 Janus kinase 2 mutation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 239000012823 PI3K/mTOR inhibitor Substances 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 229950009216 sapanisertib Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960003484 testosterone enanthate Drugs 0.000 description 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201058P | 2015-08-04 | 2015-08-04 | |
| US62/201,058 | 2015-08-04 | ||
| US201562263603P | 2015-12-04 | 2015-12-04 | |
| US62/263,603 | 2015-12-04 | ||
| PCT/US2016/045631 WO2017024171A1 (en) | 2015-08-04 | 2016-08-04 | Methods for treating myeloproliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021017312A Division JP2021066753A (ja) | 2015-08-04 | 2021-02-05 | 骨髄増殖性障害を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522039A JP2018522039A (ja) | 2018-08-09 |
| JP2018522039A5 true JP2018522039A5 (enExample) | 2019-09-12 |
| JP7320350B2 JP7320350B2 (ja) | 2023-08-03 |
Family
ID=57943723
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505460A Active JP7320350B2 (ja) | 2015-08-04 | 2016-08-04 | 骨髄増殖性障害を処置するための方法 |
| JP2021017312A Pending JP2021066753A (ja) | 2015-08-04 | 2021-02-05 | 骨髄増殖性障害を処置するための方法 |
| JP2023083682A Pending JP2023096173A (ja) | 2015-08-04 | 2023-05-22 | 骨髄増殖性障害を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021017312A Pending JP2021066753A (ja) | 2015-08-04 | 2021-02-05 | 骨髄増殖性障害を処置するための方法 |
| JP2023083682A Pending JP2023096173A (ja) | 2015-08-04 | 2023-05-22 | 骨髄増殖性障害を処置するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9884900B2 (enExample) |
| EP (2) | EP3331550B1 (enExample) |
| JP (3) | JP7320350B2 (enExample) |
| KR (2) | KR102824235B1 (enExample) |
| CN (2) | CN108348578B (enExample) |
| AU (2) | AU2016301380B2 (enExample) |
| CA (1) | CA2994413A1 (enExample) |
| HK (1) | HK1256638A1 (enExample) |
| WO (1) | WO2017024171A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| CN120919282A (zh) | 2013-11-21 | 2025-11-11 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| CN110050000B (zh) * | 2017-05-12 | 2022-07-26 | 苏州盛迪亚生物医药有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| WO2018231905A1 (en) * | 2017-06-14 | 2018-12-20 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
| CN119431579A (zh) | 2018-03-09 | 2025-02-14 | 艾吉纳斯公司 | 抗cd73抗体及其使用方法 |
| US20210113524A1 (en) * | 2018-05-31 | 2021-04-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of treating myeloproliferative disorders |
| MY209349A (en) * | 2018-09-25 | 2025-07-03 | Impact Biomedicines Inc | Methods of treating myeloproliferative disorders |
| EP4003399A4 (en) * | 2019-07-26 | 2023-04-26 | Board Of Trustees Of Michigan State University | METHODS OF PREVENTING OR TREATMENT OF FATTY ACID DEGENERATION OF SKELETON MUSCLES |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| WO2021067749A2 (en) * | 2019-10-02 | 2021-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the treatment of osteoarthritis |
| US12527839B2 (en) | 2019-11-05 | 2026-01-20 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| RS65326B1 (sr) | 2020-12-18 | 2024-04-30 | Nuvamid Sa | Derivati nikotinamid mononukleotida u lečenju i prevenciji bolesti srpastih ćelija |
| US20250325549A1 (en) * | 2021-08-18 | 2025-10-23 | Samyang Holdings Corporation | Oral tablet composition of ruxolitinib and method for preparing same |
| WO2026064424A1 (en) * | 2024-09-17 | 2026-03-26 | The General Hospital Corporation | System for and method of personalized screening and diagnosis with hematological setpoints |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ZA914750B (en) | 1990-06-20 | 1992-03-25 | Bristol Myers Squibb Co | Methods of modulating blood pressure using tgf-beta and antagonists thereof |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| AU671606B2 (en) | 1991-10-31 | 1996-09-05 | Whitehead Institute For Biomedical Research | TGF-beta type receptor cDNAs and uses therefor |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5543143A (en) | 1992-03-06 | 1996-08-06 | Corixa Corporation | Method for activating macrophages/monocytes |
| AU669256B2 (en) | 1992-10-29 | 1996-05-30 | Celtrix Pharmaceuticals, Inc. | Uses of TGF-beta receptor fragment as a therapeutic agent |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| DE69434934D1 (de) | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US5866323A (en) | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| US6423501B2 (en) | 1996-12-13 | 2002-07-23 | Beth Israel Deaconess Medical Center | Calcium-independent negative regulation by CD81 of receptor signaling |
| CN1257545A (zh) | 1997-04-18 | 2000-06-21 | 拜奥根有限公司 | Ⅱ型TGF－β受体/免疫球蛋白恒定区融合蛋白 |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6011577A (en) | 1997-06-30 | 2000-01-04 | Polaroid Corporation | Modular optical print head assembly |
| MY131805A (en) | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO1999065948A1 (en) | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| CA2355215A1 (en) | 1998-12-28 | 2000-07-06 | Jim Wells | Identifying small organic molecule ligands for binding |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE60042021D1 (de) | 1999-07-29 | 2009-05-28 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| PT1263464E (pt) | 2000-03-09 | 2012-12-17 | Genzyme Corp | Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal |
| AU2001249446A1 (en) | 2000-03-24 | 2001-10-08 | Dzgenes, L.L.C. | Diagnostic polymorphisms of tgf-beta-rii promoter |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US20030028905A1 (en) | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
| US20030180301A1 (en) | 2002-01-22 | 2003-09-25 | Shaf Keshavjee | Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| AU2003297460A1 (en) | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| SG145713A1 (en) | 2003-08-13 | 2008-09-29 | Univ Illinois | SILENCING OF TGFss TYPE II RECEPTOR EXPRESSION BY SIRNA |
| CN1838958A (zh) | 2003-08-22 | 2006-09-27 | 贝林格尔·英格海姆药物公司 | 治疗慢性阻塞性肺病和肺动脉高血压的方法 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7786261B2 (en) | 2004-09-02 | 2010-08-31 | National Research Council Of Canada | Coiled-coil fusion proteins comprising cell receptor domains |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN101084007A (zh) | 2004-09-22 | 2007-12-05 | 金齐姆公司 | TGF－β拮抗剂限制免疫抑制剂肾毒性的用途 |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| JP5481028B2 (ja) | 2004-10-13 | 2014-04-23 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | ウイルス関連リンパ増殖性障害を処置または予防するための方法 |
| FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| CA2597098C (en) | 2005-02-08 | 2016-08-02 | Steven R. Ledbetter | Antibodies to tgfbeta |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP5342834B2 (ja) | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| ITMI20060181A1 (it) | 2006-02-03 | 2007-08-04 | Univ Padova | Modulatori del tgf-b e loro uso |
| EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP2029625A2 (en) | 2006-06-05 | 2009-03-04 | Novartis AG | Use of tgf-beta antagonists in treatment of parathyroid-related disorders |
| CN101553254A (zh) | 2006-10-03 | 2009-10-07 | 建新公司 | TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途 |
| WO2008113185A1 (en) | 2007-03-19 | 2008-09-25 | National Research Counsil Of Canada | Antagonists of ligands and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| JP2010529859A (ja) | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質 |
| EA017392B1 (ru) | 2007-08-22 | 2012-12-28 | Айрм Ллк | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ |
| EP2238241B1 (en) | 2008-01-18 | 2013-09-11 | The Brigham and Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
| US20110104121A1 (en) | 2008-05-21 | 2011-05-05 | Wira Charles R | Female Reproductive Tract and Anal Prophylaxes |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| JP2011526794A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＧＦ−βアンタゴニスト多重標的結合性分子 |
| US20120010178A1 (en) | 2008-10-21 | 2012-01-12 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| WO2010129515A1 (en) | 2009-05-08 | 2010-11-11 | The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services | Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma |
| EP2524038A4 (en) | 2010-01-12 | 2013-11-20 | Isis Pharmaceuticals Inc | MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN101852804B (zh) | 2010-03-29 | 2013-06-12 | 中国医学科学院病原生物学研究所 | Gdf15蛋白的抗体的新用途 |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| CA2809568C (en) | 2010-09-01 | 2019-06-11 | Genzyme Corporation | Treatment of myocardial infarction using tgf - beta antagonists |
| US20130287688A1 (en) | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| US8800906B2 (en) | 2010-12-27 | 2014-08-12 | The Board Of Trustees Of The Leland Stanford Junior University | Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain |
| US9150651B2 (en) | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
| EP3549952A1 (en) | 2011-04-20 | 2019-10-09 | Acceleron Pharma Inc. | Endoglin polypeptides and uses thereof |
| CN102850458B (zh) * | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| WO2013019805A1 (en) | 2011-08-01 | 2013-02-07 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
| WO2013059879A1 (en) | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| WO2013173307A1 (en) | 2012-05-16 | 2013-11-21 | Neil Desai | Multi-target modulation for treating fibrosis and inflammatory conditions |
| JP6495884B2 (ja) | 2013-03-11 | 2019-04-03 | ジェンザイム・コーポレーション | 改変抗ｔｇｆベータ抗体および抗原結合フラグメント |
| MY186864A (en) | 2013-03-12 | 2021-08-26 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
| WO2014172584A1 (en) | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| DE102013109400A1 (de) * | 2013-08-29 | 2015-03-05 | Harting Kgaa | Kontaktelement mit Goldbeschichtung |
| CN120919282A (zh) | 2013-11-21 | 2025-11-11 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| DK3145493T3 (da) | 2014-05-18 | 2022-10-31 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende exosomer |
| JP6820748B2 (ja) | 2014-06-13 | 2021-01-27 | ノバルティス アーゲー | Ｇｄｆ−１５を減少させるためのセレラキシンの使用 |
| CN106794233B (zh) | 2014-08-01 | 2021-11-12 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| WO2017134592A1 (en) | 2016-02-03 | 2017-08-10 | Biocon Limited | Anti-cd20/immunomodulatory fusion proteins and methods for making same |
| JP7573365B2 (ja) | 2016-08-12 | 2024-10-25 | メルク パテント ゲーエムベーハー | 癌の併用療法 |
| US10906957B2 (en) | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| CN110198738A (zh) | 2017-01-07 | 2019-09-03 | 默克专利有限公司 | 用于靶向的TGF-β抑制的给药方案和剂型 |
| IL268995B2 (en) | 2017-03-02 | 2024-02-01 | Nat Res Council Canada | TGF-B receptor ectodomain fusion compounds and their uses |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| US12364736B2 (en) | 2018-02-09 | 2025-07-22 | Acceleron Pharma Inc. | Methods for treating heterotopic ossification |
-
2016
- 2016-08-04 WO PCT/US2016/045631 patent/WO2017024171A1/en not_active Ceased
- 2016-08-04 EP EP16833893.7A patent/EP3331550B1/en active Active
- 2016-08-04 KR KR1020187006105A patent/KR102824235B1/ko active Active
- 2016-08-04 US US15/228,956 patent/US9884900B2/en active Active
- 2016-08-04 CN CN201680057745.9A patent/CN108348578B/zh active Active
- 2016-08-04 CA CA2994413A patent/CA2994413A1/en active Pending
- 2016-08-04 KR KR1020257020329A patent/KR20250093593A/ko active Pending
- 2016-08-04 JP JP2018505460A patent/JP7320350B2/ja active Active
- 2016-08-04 HK HK18115773.1A patent/HK1256638A1/zh unknown
- 2016-08-04 AU AU2016301380A patent/AU2016301380B2/en active Active
- 2016-08-04 CN CN202210859131.XA patent/CN116327952A/zh active Pending
- 2016-08-04 EP EP22204672.4A patent/EP4218792A1/en not_active Withdrawn
-
2017
- 2017-12-14 US US15/842,300 patent/US11203624B2/en active Active
-
2021
- 2021-02-05 JP JP2021017312A patent/JP2021066753A/ja active Pending
- 2021-09-24 AU AU2021236561A patent/AU2021236561A1/en not_active Abandoned
- 2021-11-24 US US17/535,100 patent/US20220332778A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083682A patent/JP2023096173A/ja active Pending
-
2024
- 2024-05-01 US US18/651,770 patent/US20250042963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522022A5 (enExample) | ||
| Krause et al. | Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study | |
| ES2913208T3 (es) | Tratamientos de combinación y usos y métodos de los mismos | |
| US11878061B2 (en) | Methods for improving the therapeutic index for a chemotherapeutic drug | |
| Moreno et al. | Targeting the T helper 2 inflammatory axis in atopic dermatitis | |
| Moltó et al. | Anti-IL-1 molecules: new comers and new indications | |
| US20240190984A1 (en) | Methods of treating multiple myeloma | |
| JP2017031209A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| TW201936600A (zh) | 以ccr6或cxcr2之拮抗劑治療廣泛性膿疱型乾癬之方法 | |
| JP2021006543A (ja) | 好酸球又はマスト細胞関連障害の治療 | |
| WO2019213686A1 (en) | Therapeutic compositions and uses therefor | |
| TW202124443A (zh) | 高親和力的、配位基阻斷性、人源化的抗T細胞免疫球蛋白結構域和黏蛋白結構域3(TIM-3)IgG4抗體用於治療骨髓纖維化之用途 | |
| KR20160044035A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| KR20210090211A (ko) | 거대 세포 동맥염에 대한 치료 | |
| TWI899163B (zh) | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 | |
| KR20210003086A (ko) | 항-p-셀렉틴 항체의 용도 | |
| Redgrave et al. | Exogenous TGFβ1 and its mimic HpTGM attenuate the heart’s inflammatory response to ischaemic injury and improve long term cardiac outcomes | |
| WO2024263798A1 (en) | Compositions comprising antineoplastons and methods of treating prostate cancer | |
| WO2024263963A2 (en) | Compositions comprising antineoplastons and methods of treating head and neck cancer | |
| EP4731199A2 (en) | Compositions comprising antineoplastons and methods of treating colorectal cancer | |
| WO2024263960A2 (en) | Compositions comprising antineoplastons and methods of treating lung cancer | |
| WO2024263643A1 (en) | Compositions comprising antineoplastons and methods of treating breast cancer | |
| WO2024263801A2 (en) | Compositions comprising antineoplastons and methods of treating ovarian cancer | |
| EP4731793A2 (en) | Compositions comprising antineoplastons and methods of treating pancreatic cancer | |
| KR20240112966A (ko) | 항-gd2 투여 용법 |